Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.

Wallis, RS; Maeurer, M; Mwaba, P; Chakaya, J; Rustomjee, R; Migliori, GB; Marais, B; Schito, M; Churchyard, G; Swaminathan, S; +2 more... Hoelscher, M; Zumla, A; (2016) Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. The Lancet infectious diseases, 16 (4). e34-46. ISSN 1473-3099 DOI: https://doi.org/10.1016/S1473-3099(16)00070-0

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S1473-3099(16)00070-0

Abstract

Share

Download

Full text not available from this repository.

Downloads

View details

Metrics & Citations


Google Scholar